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Abstract 
Coronary atherosclerotic disease is highly prevalent in chronic kidney disease (CKD). Although 
revascularization improves outcomes, procedural risks are increased in CKD and unbiased data 
comparing bypass surgery (CABG) and percutaneous intervention (PCI) in CKD are sparse. To 
compare outcomes of CABG and PCI in stage 3-5 CKD, we systematically identified 
randomized trials comparing CABG and PCI. Investigators were contacted and individual, 
patient-level data obtained. Ten trials enrolling 3993 subjects out of 27 meeting inclusion criteria 
provided data. These trials included 526 subjects with stage 3-5 CKD including 137 with stage 
3b-5 CKD. Among individuals with stage 3-5 CKD (HR 0.99, 95% CI: 0.67, 1.46) or stage 3b-5 
CKD (HR 1.29, 95% CI: 0.68, 2.46) survival through 5-years was not different following CABG 
compared with PCI. In contrast, CKD modified the impact on survival free from myocardial 
infarction (Pinteraction=0.04), which did not differ between CABG and PCI for individuals with 
preserved kidney function (HR 0.97, 95% CI: 0.80, 1.17), but was lower following CABG in 
stage 3-5 CKD (HR 0.49, 95% CI: 0.29, 0.82) and stage 3b-5 CKD (HR 0.23, 95% CI: 0.09, 
0.58). Repeat revascularization was reduced following CABG compared with PCI regardless of 
baseline kidney function. Results were limited by unavailability of data from several trials and 
the small number of enrolled subjects with stage 4-5 CKD. Our patient-level meta-analysis of 
individuals with CKD randomized to CABG versus PCI suggests that CABG significantly 
reduces the risk of subsequent MI and revascularization without impacting survival in these 
patients. 
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Introduction 
More than 10% of the adult U.S. population have chronic kidney disease (CKD)1, which 
is associated with increased cardiovascular morbidity and mortality2, 3. Standard cardiovascular 
therapies have the potential to decrease morbidity and mortality, but utilization of established 
cardiovascular therapies including coronary angiography and revascularization procedures has 
remained lower in individuals with CKD than in patients with relatively preserved kidney 
function.4, 5 
Although this selective underutilization of coronary revascularization in a population at 
high cardiovascular risk (“renalism”5) could represent inappropriate therapeutic nihilism, recent 
trials have failed to demonstrate efficacy of standard medical therapies in patients on dialysis6, 7 
while the majority of large cardiovascular trials have excluded individuals with CKD raising 
important questions about the efficacy or safety of other accepted cardiovascular therapies in 
this population. Indeed, patients with CKD experience higher perioperative mortality8, 9 following 
coronary artery bypass grafting (CABG), are at higher risk of acute kidney injury following CABG 
surgery or percutaneous coronary intervention (PCI)10, 11, and have generally much higher 
overall mortality12, 13 compared with the subjects enrolled in landmark trials comparing CABG 
and PCI, in whom advanced kidney dysfunction was uncommon8. Therefore, a dedicated, CKD-
specific comparison of the risks and benefits of PCI and CABG is needed to define the optimal 
role for each therapy in the setting of impaired kidney function.   
 Although several retrospective comparisons of PCI and CABG among individuals with 
CKD undergoing coronary revascularization for clinical indications have generally favored 
CABG14-16, the potential for indication bias and residual confounding remains an important 
concern with non-randomized studies in this area. To provide highest-level evidence, we 
conducted a systematic review of the literature and, subsequently, a detailed, individual-level 
meta-analysis of patients with moderate to severe CKD from published randomized trials 
comparing CABG and PCI. 
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Results 
Study Identification and Characteristics 
Our pre-specified literature search identified 1111 citations (Figure 1). After title and 
abstract review, 75 citations were examined in detail; however, 48 were excluded because they 
failed to meet the specified inclusion criteria. A total of 27 eligible trials were identified for 
inclusion, but 17 had to be excluded for the following reasons: data no longer available (n=3)17-
19; insufficient data to calculate eGFR (n=7)20-26unable to contact the investigators despite 
multiple attempts (n=3)27-29; investigators unable (n=2)30, 31 or unwilling (n=2)32, 33 to share data.    
The remaining 10 trials comprised the analytical dataset and included the following trials: 
AMIST34; Bypass Angioplasty Revascularization Investigators Trial (BARI)35; Cisowski et al. 36; 
Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass 
Surgery in Multivessel Disease (ERACI II)37; German Angioplasty Bypass Surgery Investigation 
(GABI)38; Left Main Stenting (Le MANS)39; Leipzig40; Medicine, Angioplasty or Surgery Study 
(MASS 1)41; Medicine, Angioplasty or Surgery II Study (MASS 2)42; and Veterans Affairs 
Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (VA 
[AWESOME])43.  
All studies used central and concealed randomization and intention to treat analyses of 
outcomes. However, in 2 studies, outcomes assessors were not blinded to treatment 
assignment.34, 36  Loss to follow-up was generally low, but exceeded 10% in 2 studies34, 38 
(Table 1).  
 The majority of trials completed enrollment between 1991 and 2001 with exception of a 
single trial that completed enrollment in 200236 and the Le Mans trial, which enrolled subjects 
from 1997-200839. As shown in Table 1, stents were utilized in all but 2 studies38, 41, and off-
pump bypass techniques were available for CABG patients in 5 studies34, 36, 39-41. Four studies 
required multi-vessel disease for inclusion35, 37, 38, 42 while 4 excluded individuals with multi-
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vessel coronary disease34, 36, 40, 41. One study (AMIST)34 did not collect data on at least one 
covariate leading to systematic missingness.  Eligible studies for which we were unable to 
obtain data were qualitatively similar to included studies in terms of sample size, year enrolled, 
revascularization technique, inclusion criteria and the range of relative risks of study outcomes 
following PCI compared with CABG (Supplementary Tables 4 & 5). 
 
Baseline Characteristics of Study Subjects 
 The study cohort included 3993 randomized subjects (CABG: 1994, PCI: 1999,) with 
17,131 person-years (PY) of post-intervention follow-up time (post-CABG: 8528 PY, post-PCI: 
8603 PY). There were 526 individuals with stage 3 or worse CKD with 1856 PY of follow-up 
(CABG: 892 PY, PCI: 964 PY), and 137 with stage 3b or worse CKD (20 with stage 4-5 CKD) 
with 402 PY of follow-up (CABG: 195 PY, PCI: 207 PY).  There were 7 individuals with stage 5 
CKD. Baseline characteristics of the enrolled patients and those with CKD are shown in Tables 
2 and 3. Individuals with and without CKD were mostly similar, but those with CKD tended be 
older and a higher percentage of those with CKD were female. 
  
Survival 
 All-cause mortality rates were similar following CABG or PCI, and were higher among 
individuals with CKD (CABG: 5.6/100 PY, PCI: 5.5/100 PY) compared to those with preserved 
kidney function (CABG: 2.1/100 PY, PCI: 2.3/100 PY).  
 In primary multiple imputation-based analysis adjusted for all covariates of interest, 
mortality did not differ between patients randomized to CABG versus PCI among individuals 
with relatively preserved kidney function (HR 0.90, 95% CI: 0.73, 1.11), those with stage 3-5 
CKD (HR 0.99, 95% CI: 0.67, 1.46), those with stage 3a CKD (HR 0.79, 95% CI: 0.47, 1.33), or 
those with stage 3b-5 CKD (HR 1.29, 95% CI: 0.68, 2.46; Figure 2A-C). In the overall cohort, 
there was no significant evidence for effect modification by the presence of CKD 
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(Pinteraction=0.52). Among individuals with CKD there was no significant effect modification on 
survival according to the presence of proximal left anterior descending artery stenosis 
(Pinteraction=0.88) or according to the presence or absence of multi-vessel disease 
(Pinteraction=0.13). Results were similar in crude and adjusted analyses (Table 4).  For the 
subgroup with stage 3-5 CKD, the I2 statistic (0.0%) was consistent with minimal between-study 
heterogeneity. 
 Short-term results at 1 year were qualitatively similar to 5-year outcomes.  Adjusted risks 
of mortality did not differ 1 year after CABG compared with PCI among individuals with 
preserved kidney function (HR 1.35, 95% CI: 0.95, 1.93), those with stage 3-5 CKD (HR 0.92, 
95% CI: 0.54, 1.58), those with stage 3a CKD (HR 0.73, 95% CI: 0.35-1.54), or those with stage 
3b-5 CKD (HR 1.28, 95% CI: 0.56, 2.95). 
 
 
Myocardial Infarction 
 Among individuals with CKD, non-fatal MI rates were higher after PCI (5.1/100 PY) than 
CABG (2.7/ 100 PY, P=0.01) whereas the rates were similar after PCI (2.9/100 PY) and CABG 
(2.9/100 PY, P=0.95) amongst individuals with preserved kidney function. Among individuals 
with CKD 13.2% died within 30 days of an MI compared with 7.3% among those with preserved 
renal function. 
 In primary analysis models, the risk of non-fatal MI among individuals with preserved 
kidney function (HR 0.97, 95% CI: 0.80, 1.17) did not differ between the two treatments, 
whereas MI risk among patients  was lower following CABG compared with PCI in those with 
stage 3-5 CKD (HR 0.49, 95% CI: 0.29, 0.82) and stage 3a CKD (HR 0.70, 95% CI: 0.36, 1.39), 
and was even lower among those with stage 3b-5 CKD (HR 0.23, 95% CI: 0.09, 0.58).  A 
significant test of interaction in analyses of the full cohort was consistent with effect modification 
by the presence versus absence of stage 3-5 CKD (Pinteraction=0.04). Among individuals with 
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CKD, CABG provided similar benefits between individuals with and without multi-vessel disease 
(Pinteraction=0.13) and between those with versus without proximal LAD disease (Pinteraction=0.32). 
Results were qualitatively similar in crude and adjusted analyses (Table 5).  For the subgroup 
with stage 3-5 CKD, the I2 statistic (0.0%) was consistent with minimal between-study 
heterogeneity. 
 Short-term results at 1 year were similar to 5-year outcomes.  Adjusted risks of MI did 
not differ 1 year after CABG compared with PCI among individuals with preserved kidney 
function (HR 1.17, 95% CI: 0.92, 1.49), but were lower following CABG compared with PCI in 
those with stage 3-5 CKD (HR 0.44, 95% CI: 0.23, 0.81), those with stage 3b-5 CKD (HR 0.18, 
95% CI: 0.05, 0.58), and were not significantly lower among those with stage 3a CKD (HR 0.59, 
95% CI: 0.28-1.28). 
 
 
Repeat Revascularization 
 
 Repeat revascularization was conducted more frequently after PCI than CABG (Figure 2) both 
among individuals with CKD (7.2 cases/100 PY versus 1.4 cases/100 PY, P<0.001) and those 
with preserved kidney function (13.7 cases/100 PY versus 1.7 cases/100 PY, P<0.001). Risk 
reduction associated with revascularization was similar for individuals with preserved kidney 
function (HR 0.14, 95% CI: 0.11, 0.17), those with stage 3-5 CKD (0.21, 95% CI: 0.11, 0.39), 
those with stage 3a CKD (HR 0.17, 95% CI: 0.08, 0.40) and those with stage 3b-5 CKD (HR 
0.25, 95% CI: 0.09, 0.71). There was no evidence of effect modification by the presence of 
CKD, Pinteraction=0.26). Tests of interaction with multi-vessel disease (Pinteraction=0.93) or proximal 
LAD involvement (Pinteraction=0.90) were also non-significant. Results were similar in crude and 
adjusted models (Table 6).  For the subgroup with stage 3-5 CKD, the I2 statistic (25.3%) was 
consistent with minimal between study heterogeneity. 
 Short-term results at 1 year were similar to 5-year outcomes.  Adjusted risks of 
revascularization were lower 1 year after CABG compared with PCI among individuals with 
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preserved kidney function (HR 0.08, 95% CI: 0.06, 0.11), as well as those with stage 3-5 CKD 
(HR 0.14, 95% CI: 0.06, 0.30), those with stage 3a CKD (HR 0.12, 95% CI: 0.04-0.33), or those 
with stage 3b-5 CKD (HR 0.17, 95% CI: 0.05, 0.61). 
Sensitivity Analyses 
 Results of models with differing levels of covariate adjustment, excluding studies with 
systematic missingness, or using complete-case analysis rather than multiple imputation were 
qualitatively similar to our main findings (Supplementary Tables).  
 
Acute Dialysis and Hospitalization 
 Information on dialysis was not available for GABI.  In the remaining trials, there were 8 
(0.5%) cases of dialysis requiring acute kidney injury (AKI) in the PCI group and 5 (0.3%) cases 
in the CABG group. Among individuals with stage 3-5 CKD there were 5 (2.4%) cases in the 
PCI group and 2 cases (1.1%) in the CABG group. The risk of dialysis-dependent AKI did not 
differ significantly with CABG compared to PCI overall (odds ratio [OR] 0.61, 95% CI 0.20, 
1.88), those with preserved kidney function (OR 0.98, 95% CI: 0.20, 4.85), or those with stage 
3-5 CKD (OR 0.41, 95% CI: 0.08, 2.15), or stage 3b CKD (OR 0.71, 95% CI: 0.10, 5.23). 
 Data on cardiovascular hospitalizations was available from 6 trials.36, 38, 39, 41-43 CABG 
was generally associated with lower risks of hospitalization than PCI.  At 5-years, the adjusted 
risk was lower after CABG than PCI among those with preserved kidney function (HR 0.30, 95% 
CI: 0.23, 0.39), those with stage 3-5 CKD (0.43, 95% CI: 0.27, 0.71), and those with stage 3a 
CKD (HR 0.32, 0.17, 0.60).  CV hospitalization rates were lower but the change in risk was not 
significant with stage 3b-5 CKD (HR 0.77, 95% CI: 0.35, 1.72).  There was no evidence of effect 
modification according to the presence of CKD (Pinteraction=0.19).  For the subgroup with stage 3-
5 CKD, the I2 statistic (1.0%) was consistent with minimal between study heterogeneity. 
Results during the first year were qualitatively similar to those at 5 years (data not shown).   
Discussion 
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 Although CKD is a common condition1 with high risks of cardiovascular morbidity and 
mortality3, high quality evidence to guide the use of PCI versus CABG in the setting of 
significant kidney impairment has been lacking. To better understand the risks and benefits of 
coronary revascularization in individuals with CKD, we analyzed individual, patient-level data 
from almost four thousand individuals enrolled in 10 trials in which patients were randomized to 
receiving CABG or PCI. To our knowledge, the 526 individuals with CKD that we identified 
represent the largest randomly assigned cohort comparing the risks of benefits of CABG and 
PCI in the setting of CKD. 
We found that for individuals with stage 3-5 CKD in whom both CABG and PCI were 
clinically indicated and technically feasible, there were no significant differences in mortality with 
either approach to revascularization. However, despite the similarities in mortality, CABG 
strongly reduced both the risks of MI and the need for additional revascularization procedures 
without evidence for significant effect modification by the presence of single compared with 
multi-vessel disease. The present study provides important new evidence informing the decision 
faced by clinicians and their patients with CKD who require coronary intervention and have to 
decide between CABG and PCI.  
While we are unaware of any published clinical trials specifically randomizing individuals 
with CKD to CABG versus PCI, several observational studies have suggested that CABG was 
associated with lower mortality than PCI in the setting of CKD15, 44-46, and at least one suggested 
that the mortality benefit increased as eGFR declined15. In contrast, a study by Szczech47 was 
consistent with our findings. This study may more closely resemble the randomized population 
we studied as it specifically excluded subjects belonging to anatomic subgroups with grossly 
unbalanced utilization of CABG and PCI (suggesting non-comparability of the indication for 
revascularization), and it did not find a survival benefit from CABG among individuals with 
serum creatinine ≥2.5 mg/dL.   
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In contrast with some observational studies, our findings are mostly consistent with a 
prior analysis by Ix et al. of 290 randomized participants with CKD from the Arterial 
Revascularization Therapies Study48 in which CABG did not impact mortality (HR 0.93, 95% CI 
0.54-1.60) compared with PCI, but led to a significant reduction in the need for repeat 
revascularization (HR 0.28, 95% CI: 0.14-0.54). Both results were confirmed by our analysis 
although the primary investigator of the Arterial Revascularization Therapies Study did not grant 
access to their data for our study. Our results differ, however, in that the former study did not 
demonstrate significant reductions in the risk of MI (HR 1.34, 95% CI: 0.55-3.23). However, the 
confidence intervals around this estimate were wide because of low the number of MI events 
(n=20). By contrast, we found a strong reduction in MI risk from CABG that also appeared to 
increase with decreasing kidney function. Therefore, owing to nearly double the number of 
participants, a larger number of events within the CKD population (103 deaths, 68 MIs, 65 
repeat revascularizations), and a more clinically relevant duration of follow-up (5 versus 3 
years), our analysis extends the findings by Ix et al. in several important ways. In particular, our 
cohort included subjects from multiple trials with a more generalizable set of inclusion criteria 
that more broadly represent the range of clinical indications for revascularization than the 
Arterial Revascularization Therapies Study48, which included only subjects with multi-vessel 
disease and excluded subjects with overt congestive heart failure. Finally, the use of an 
individual patient data from multiple trials allowed us to adjust for multiple covariates 
simultaneously, which would not have been possible using traditional meta-analytic techniques.  
Taken together, our study and the one by Ix et al48 suggest that prior observational 
analyses showing large survival benefits may have overestimated the mortality benefits of 
CABG compared with PCI in the setting of CKD. In fact, observational studies have consistently 
demonstrated increasing risks of operative death as kidney function declines49, and our 
estimates  do not rule out worsened survival following CABG compared with PCI among 
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subjects with the most advanced CKD—although confidence intervals around these estimates 
were very wide.  
 Indication bias or residual confounding via selective utilization of CABG in those 
individuals with the best underlying prognosis or with anatomic features most clearly favorable 
to surgical revascularization or, conversely, selective use of PCI in patients with very high 
operative risk, may have driven prior findings of a survival benefit with CABG compared with 
PCI in the setting of CKD. Although our findings do not support a conclusion that CABG reduces 
the hazard of mortality compared to PCI when both CABG and PCI are anatomically and 
clinically feasible, we did find that among CKD patients, CABG was associated with dramatically 
lower risks of MI and repeat revascularization during follow-up. Thus, CABG may be the 
preferable procedure that reduces overall morbidity despite not conferring a survival advantage. 
Our study had certain limitations that require consideration. Unfortunately, despite 
including data from the largest number of trials and including the largest reported number of 
randomized patients with CKD (particularly those with ≥stage 3b disease), numerous trials 
either no longer had data available or failed to collect sufficient information to calculate eGFR. 
We were also unable to obtain data from several additional trials despite several attempts. The 
majority of trials were completed before IDMS-traceable creatinine assays were in wide use, 
and we did not have access to the assays used for creatinine testing. The lack of 
standardization or calibration may have led to some imprecision in estimation of GFR, although 
this should be balanced in the two treatment groups. In addition, for the BARI trial35 we were 
unable to obtain the actual creatinine, and instead had to use a threshold value, as described 
above. Although we are confident with the specificity of this approach for the identification of 
CKD, some patients with moderate CKD may have been missed. 
We were also unable to standardize outcomes or baseline variable definitions across 
trials. We cannot rule out the possibility that different assessments across trials could have 
impacted our findings. Lastly, most of the included trials were completed more than a decade 
Charytan et al, CABG versus PCI in CKD 
ago. Whether results would differ in the context of contemporary medical therapy, newer 
revascularization techniques, or for subjects not meeting the entrance criteria of these trials 
cannot be answered by our analysis, and results should be extrapolated cautiously. 
Finally, our study does not address the gaping hole in the evidence on how to best treat 
patients with severe kidney dysfunction who require revascularization including those with end-
stage kidney disease requiring dialysis or kidney transplantation. Indeed, an important finding of 
our analysis is that among nearly 4000 patients included in a series of randomized trials that 
helped establish the standard of care for coronary artery disease only 137 had stage 3b or 
worse CKD, only 20 had stage 4-5 CKD, and none had ESRD. Assuming that trial practices 
have not changed, this finding raises serious questions about the extrapolation of standard of 
care practices to the care of those at the most advanced stages of CKD. 
In conclusion, our study provides the highest-quality evidence to date regarding the 
morbidity and mortality benefits of CABG compared with PCI in the setting of CKD. While 
survival was similar following CABG and PCI, we found that CABG significantly reduced the risk 
of subsequent MI or revascularization procedures. In the absence of additional randomized 
data, our analysis should be reassuring to clinicians who can counsel individuals requiring 
coronary revascularization that benefits of CABG do not appear to be attenuated in the setting 
of moderate CKD and that surgical revascularization is more likely than PCI to prevent 
subsequent MI or revascularization without adversely impacting survival. Finally, the hypothesis 
generating findings indicating worse survival with CABG in the small subsample of patients with 
Stage 3b and 4-5 CKD should provide additional motivation for performing randomized studies 
specifically enrolling individuals with advanced CKD or ESRD in order to provide better answers 
on risks and benefits in these high risk patients.  
 
 
Methods 
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Search Criteria and Identification of Eligible Trials 
We searched MEDLINE, EMBASE and Cochrane databases (Ovid Technologies 1950-
September 2010) for keywords related to coronary revascularization procedures including, 
“angioplasty, transluminal, percutaneous coronary, and coronary artery bypass”. The search 
was limited to randomized controlled trials (not valid within EMBASE), humans, and English 
language publications. Following automated removal of duplicate citations, results of the 
computerized search were independently reviewed in duplicate by 2 investigators (DMC, NMS, 
or WCW) to identify unique, randomized trials comparing CABG and PCI. The reference lists of 
identified trials and relevant meta-analyses were subsequently reviewed for studies not 
identified electronically. Trials that randomly allocated patients to CABG or PCI were considered 
for inclusion without further restriction. The manuscript reporting the primary endpoint results 
was used to identify trials and investigators.  Additional detail on the research plan and 
modifications to the study protocol are provided in the Supplementary Appendix.  The PRISM 
individual patient meta-analysis statement was used as a guideline for structuring the 
manuscript.50  
 
Data Extraction 
The majority of identified studies had not published CKD-specific results. Investigators 
from each trial were therefore contacted and asked to prepare and share data on trial 
characteristics and individual, patient-level data including serum creatinine, baseline 
characteristics, interventions, and selected outcomes for enrolled subjects. Multiple attempts 
were made to contact study investigators before determining investigators’ status as 
unreachable. Provided data sets were individually cleaned and compared against trial 
publications for consistency with baseline characteristics and main outcomes. Trial investigators 
were re-contacted and queried as needed to ensure fidelity, accuracy, and completeness of final 
data sets.  
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Kidney Function 
Kidney function was determined using the estimated glomerular filtration rate (eGFR), 
which was calculated using the CKD-EPI equation51 from baseline serum creatinine 
concentrations, age, sex, and race. The Bypass Angioplasty Revascularization Investigation  
(BARI) trial recorded only a dichotomized kidney dysfunction variable according to whether 
serum creatinine was >1.5 mg/dL but did not record the actual baseline values35. Therefore the 
theoretical maximum value of eGFR was calculated for BARI subjects using a creatinine of 1.6 
mg/dL for individuals above this threshold and 0.1 mg/dL for individuals below this threshold. 
Given the primary analytic goal of assessing effects of CABG versus PCI in CKD patients, this 
approach was adopted in order to ensure a high specificity of the CKD definition for BARI 
subjects despite the possibility of misclassifying some BARI subjects with less significantly 
elevated creatinine as having preserved kidney function. Stages of CKD were defined as stage 
3a (eGFR 45-59 mL/min/1.73m2), stage 3b (eGFR 30-44 mL/min/1.73m2), stage 4 (eGFR 15-29 
mL/min/1.73m2), or stage 5 CKD (eGFR <15mL/min/1.73m2 or dialysis-dependent) according to 
the 2012 updates of the KDOQI guidelines52.  
 
Other Patient Characteristics 
Baseline demographic and clinical characteristics were assessed according to trial-
specific definitions. Covariates obtained were chosen on the basis of availability and well-
established associations with outcomes and included assigned treatment, age, race, sex, 
history of diabetes, hypertension, hyperlipidemia, congestive heart failure, prior coronary 
revascularization, history of prior myocardial infarction (MI), presentation with MI, unstable 
angina, or elevated cardiac enzymes, ejection fraction, and coronary anatomy.  
 
Endpoints 
Charytan et al, CABG versus PCI in CKD 
Given the advanced age of the population and inconsistent data capture beyond 5 years, 
we calculated follow-up time and examined time-to-event outcomes through 5 years for the 
following events: all-cause mortality, myocardial infarction (MI), and repeat coronary 
revascularization. MI and repeat coronary revascularization outcomes were assessed according 
to the definitions originally used in the individual trials. Subjects who did not experience the 
event of interest during the study period were censored at the date of last clinical visit or 
recorded activity with right censoring at 5-years.  
 
Statistics and Analysis 
 Summary statistics are presented as counts (%) or mean ± standard deviation (SD) as 
appropriate. For the primary analyses, we used Cox proportional hazards regression models, 
stratified by trial, to model the hazard of each endpoint (all-cause mortality, MI, and repeat 
revascularization) as a function of treatment arm (PCI versus CABG), adjusting for age, 
diabetes, prior history of MI, proximal left anterior descending artery disease, ejection fraction 
<40%, prior revascularization, and multi-vessel disease. We fit models to the entire pooled 
dataset as well as within pre-defined subsets of clinical interest. Namely, subset analyses were 
conducted in subjects with: 1) preserved kidney function, 2) stage 3-5 CKD, 3) stage 3a CKD, 4) 
stage 3b-5 CKD, 5) CKD with multi-vessel disease, 6) CKD with single-vessel disease, 7) CKD 
with proximal left anterior descending [LAD] disease, or 8) CKD without proximal LAD disease.  
Kaplan-Meier estimates were used to graphically depict survival. 
 Multiple imputation was used to account for missing data. Multiple imputation is a 
statistical method used to address missing data by imputing values for missing observations 
from plausible distributions that preserve the interrelationships among the variables.53, 54 Validity 
of the results relies on the assumption that data are missing at random (MAR), or that 
missingness is related to observed features only. Specifically, for primary analyses, we imputed 
data using predictive mean matching to impute each row independently. It is critical to include 
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the outcome in the imputation model to reduce bias55; we therefore included an indicator for 
whether the observation was censored and also included the Nelson-Aalen estimator of 
cumulative hazard as a co-factor within the imputation models.56  As a sensitivity analysis, we 
imputed under a linear multilevel model that accounts for a trial-specific underlying hazard of the 
event corresponding to the study’s unique population. For this approach, computational 
limitations required the exclusion of trials (Angioplasty versus Minimally Invasive Surgery Trial, 
AMIST)34 with systematic missingness on any variable (meaning that a variable is completely 
missing within a trial).  
 We conducted sensitivity analyses manipulating 3 analytic choices in all possible 
combinations to assess the effects on point estimates of covariate adjustment, inclusion of 
studies with systematic missingness, and method of handling missing data. Firstly, we 
conducted analyses adjusting for 1) all covariates of interest, as in primary analyses, 2) a 
“minimal” subset of only those covariates that were not systematically missing by trial, or 3) no 
covariates (unadjusted estimates). Secondly, we excluded either 1) none of the 10 eligible 
studies, as in primary analyses, or 2) all studies with systematic missingness on any variable. 
Thirdly, we handled missing data either 1) via multiple imputation, as in primary analyses, or 2) 
via complete-case analysis. 
 Heterogeneity of outcomes within the CKD group was analyzed by calculating the I-
squared statistic.  Published meta-analyses comparing CABG and PCI  have not found 
evidence of publication bias.8 Given our primary aim of comparing unpublished outcomes from 
the subset of those studies with available data on renal function and the attendant analysis of 
only a minority of published studies, testing for publication bias on the included studies was not 
repeated. 
Baseline data and incidence rates and calculation of I-squared for measurement of 
heterogeneity were analyzed using STATA (version 13.0, STATA Corp, College Station, Texas). 
Multiple imputation and survival analyses were performed in R (Version 3.1.0, R Foundation for 
Charytan et al, CABG versus PCI in CKD 
Statistical Computing, Vienna, Austria)57-61. All tests were two-sided, and we defined statistical 
significance using an alpha threshold of 0.05. 
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Table 1.Trial characteristics 
Characteristic AMIST BARI 
 
Cisowski ERACI II GABI Le MANS Leipzig MASS 1 MASS 2 VA 
Central 
randomization 
+ + - + + + + + + + 
Concealed 
randomization 
+ + + + + + + + + + 
Blinded outcomes 
assessment 
- + - + + + + + + - 
Intention to treat 
analysis 
+ + + + + + + + + + 
Stents used +* + +* + - +* +* - + + 
Off-pump bypass +* - +* - - + +* - - NR 
LIMA +* + +* + + + +* +* + + 
Enrollment Period 1999-2001 1988-1991 2000-2002 1996-1998 1986-1991 1997-2008 1997-2001 1988-1991 1995-2000 1995-2000 
Single vessel 
disease only 
+ - + - - - +* +* - - 
Multi-vessel 
disease only 
- +* - +* +* - - - +* - 
Single or multi-
vessel disease 
- - - - - + - - - + 
Left main disease - - - + - +* - - - - 
NR-not recorded.  LIMA-left internal mammary artery. *Required by protocol. 
Charytan et al, CABG versus PCI in CKD 
Table 2. Baseline characteristics of trial subjects 
Characteristic 
       N (%) 
AMIST BARI 
 
Cisowski ERACI II GABI Le MANS Leipzig MASS 1 MASS 2 VA 
Year published 2004 1996 2002 2001 1994 2008 2005 1999 2002 2001 
No. of subjects 89 1829 76 450 313 82 220 141 408 385 
Age,  
  years mean (SD) 
57.7 (9.6) 61.0 (9.4) 53.4 (10.0) 60.7 (10.3) 58.9 (7.9) 61.0 (9.8) 62.0 (10.1) 56.5 (10.1) 59.7 (9.0) 67.4 (9.2) 
Male 71 (79.8) 1340 (73.3) 63 (82.9) 357 (79.3) 248 (79.2) 56 (68.3) 164 (74.6) 104 (73.8) 283 (69.4) 381 (99.0) 
White 87 (97.8) 1653 (90.4) 76 (100.0) 450 (100.0) 313 (100.0) 81 (98.8) 220 (100.0) 137 (97.2) 352 (86.3) 339 (88.1) 
Stage 3-5 CKD 18 (20.2) 43 (2.4)  11 (14.5) 111 (24.7) 51 (16.3) 16 (19.5) 30 (13.6) 25 (17.7) 83 (20.3) 138 (35.8) 
Stage 3b-5 CKD 4 (4.5) 23 (1.3) 4 (5.3) 14 (3.1) 11 (3.5) 5 (6.1) 4 (1.8) 4 (2.8) 18 (4.4) 50 (13.0) 
Diabetes -- 353 (19.3) 6 (7.9) 78 (17.3) 39 (12.6) 14 (17.1) 63 (29.6) 30 (21.3) 115 (28.2) 125 (32.6) 
Smoking -- 463 (25.3) 39 (51.3) 233 (51.8) 35 (11.8) 6 (9.0) 54 (25.4) 56 (39.8) 123 (30.2) 96 (34.0) 
Hypertension -- 896 (49.0) 42 (55.3) 318 (70.7) 130 (41.8) 76 (92.7) 152 (71.4) 43 (30.5) 253 (62.0) 267 (69.5) 
Hyperlipidemia -- 725 (44.0) 59 (77.6) 275 (61.1) 193 (62.7) 80 (97.6) 152 (71.4) 108 (76.6) 322 (78.9) -- 
Prior 
revascularization 
-- 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (7.3) 0 (0.0) 0 (0.0.) 0 (0.0) 164 (42.7) 
Prior MI -- 987 (54.5) 9 (11.8) 126 (28.0) 143 (46.3) 31 (37.8) 99 (46.5) 0 (0.0) 191 (46.8) 275 (72.0) 
CHF -- 161 (8.9) 0 (0.0 16 (3.6) 151 (48.7) 1 (1.2) -- 0 (100.0) 2 (0.5) 294 (86.5) 
Multi-vessel 
disease 
0 (0.0) 1796 (98.4) 0 (0.0) 450 (100.0) 313 (100.0) 78 (95.1) 0 (0.0) 0 (0.0) 408 (100.0) 316 (82.1) 
Left main disease 0 (0.0) 0 (0.0) 0 (0.0) 21 (4.7) 0 (0.0) 80 (97.6) 0 (0.0) 0 (0.0) 0 (0.0) 28 (7.5) 
Proximal LAD 
disease 
89 (100.0) 1081 (59.2) 76 (100.0) 230 (51.1) 90 (28.9) 28 (34.2) 220 (100.0) 141 (100.0) 381 (93.4) 221 (58.9) 
No. diseased 
vessels  
1 (0.0) 2.4 (0.5) 1 (0.0) 2.4 (0.5) 2.4 (0.5) 3.0 (1.0) 1.2 (0.4) 1 (0.0) 2.6 (0.5) 2.3 (0.8) 
Ejection Fraction, 
%, mean (SD) 
66.6 (10.6) 57.4 (11.0) 56.9 (4.9) 52.9 (5.6) 63.8 (10.6) 54.3 (8.6) 62.4(13.1) 69.2 (3.2) 67.3 (8.0) 46.0 (14.7) 
Elevated cardiac 
biomarkers on 
admission 
-- -- 0 (0.0) 87 (19.3) 0 (0.0) 6 (7.3) 0 (0.0) -- 0 (0.0) -- 
MI on admission 0 (0.0) 58 (3.2) 0 (0.0) 0 (0.0) 0 (0.0) 6 (7.4) 0 (0.0) 0 (0.0) 191 (46.8) 134 (34.8) 
Unstable angina on 
admission 
18 (21.2) 1192 (65.2) 8 (10.5) 412 (91.6) 40 (13.5) 45 (54.9) 37 (16.8) 0 (0.0) 0 (0.0) -- 
Table 1-Baseline characteristics.  Data are presented as n (%) unless otherwise noted. CKD-chronic kidney disease, CHF-congestive heart failure, LAD-left anterior descending 
artery, MI-myocardial infarction, No-number, SD-standard deviation. Data on diabetes was not available for subjects in AMIST and was missing for 3 subjects in GABI, and 2 
subjects in the VA study. Data on smoking was not available in AMIST, and was missing in 181 subjects from BARI, for 2 subject from GABI, 15 in LE MANS, 7 in Leipzig, and 103 
subjects in the VA study.  Hyperlipidemia was missing all AMIST subjects, 181 in BARI, 5 in GABI, 7 in Leipzig and all VA subjects. Data on baseline hypertension was unavailable 
in AMIST and was missing for 2 subjects from BARI, 2 in GABI, 7 in Leipzig and 1 in the VA study. Prior MI was unavailable for AMIST, and was missing in 18 subjects from BARI, 
6 subjects from GABI, 7 in Leipzig, and 3 in the VA study.  CHF was not available for AMIST participants and Leipzig and was missing in 10 subjects in BARI, 3 from GABI, and 45 
subjects from the VA study.  Prior revascularization was unavailable for AMIST and was missing 1 subject in the VA study.  Multi-vessel disease was missing in 3 subjects from 
BARI. Left main disease was missing in 10 subjects from the VA study. Proximal LAD was missing in 3 subjects in BARI, 2 in GABI, and 10 in the VA study. Data on number of 
diseased vessels was missing in 7 subjects from GABI, 3 subjects from BARI, and 6 subjects from the VA study.  Ejection fraction was missing in 55 subjects in AMIST, 475 in 
BARI 149 in GABI, 3 in Le  MANS and 98 in the VA study.  Cardiac biomarkers at baseline were not available for AMIST, BARI, VA, and MASS 1 studies.  MI on admission was 
missing in 1 subject from Le MANS.  Unstable angina at admission was missing in 4 subjects from AMIST, 17 from GABI, and all subjects in the VA study.  
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Table 3. Baseline characteristics of trial subjects with chronic kidney disease 
 
Characteristic AMIST 
(n=18) 
BARI 
(n=43) 
Cisowski 
(n=11) 
ERACI II 
(n=111) 
GABI 
(n=51) 
Le MANS 
(n=16) 
Leipzig 
(n=30) 
MASS 1 
(n=25) 
MASS 2 
(n=83) 
VA 
(n=138) 
Age,  
  years mean (SD) 
64.3 (8.9) 63.9.(8.8) 62.3 (10.0) 64.6 (9.4) 64.3 (7.0) 68.0 (8.3) 68.7 (7.2) 61.8 (9.4) 66.2 (6.5) 72.2 (6.6) 
Male 11 (61.1) 31 (72.1) 7 (63.6) 44 (39.6) 26 (51.0) 7 (43.8) 16 (53.3) 8 (32.0) 3 (63.9) 136 (98.6) 
White 18 (100.0) 33 (76.7) 11 (100.0) 111 (100.0) 51 (100.0) 16 (100.0) 30 (100.0) 25 (100.0) 76 (91.6) 122 (88.4) 
Stage 3b-5 CKD 4 (22.2) 23 (53.5) 4 (36.4) 14 (12.6) 11 (21.6) 5 (31.3) 4 (13.3) 4 (16.0) 18 (21.7) 50 (36.2) 
Stage 4-5 CKD, 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9) 4 (7.6) 1 (6.3) 0 (0.0) 0 (0.0) 4 (4.8) 10 (7.0) 
eGFR 
  mL/min/1.73m2,  
  mean (SD) 
49.8 (8.1) 43.0 (6.7) 48.3 (8.1) 50.1 (6.6) 49.7 (11.4) 46.9 (8.4) 53.1 (6.5) 52.0 (6.7) 49.0 (10.4) 46.9 (10.6) 
Diabetes -- 20 (46.5) 3 (27.3) 22 (19.8) 8 (15.7) 6 (37.5) 15 (5.7) 5 (20.0) 25 (30.1) 40 (29.0) 
Smoking -- 7 (16.3) 3 (27.3) 50 (45.1) 3 (5.9) 1 (6.7) 4 (13.8) 7 (28.0) 14 (16.9) 20 (20.2) 
Hypertension -- 33 (76.7) 8 (72.7) 91 (82.0) 32 (62.8) 16 (93.8) 28 (96.6) 7 (28.0) 58 (69.9) 113 (81.9) 
Hyperlipidemia -- 18 (48.7) 5 (45.5) 72 (64.9) 36 (70.6) 16 (100.) 18 (62.1) 19 (76.0) 61 (73.5) -- 
Prior 
revascularization 
-- 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 4 (25.0) 0 (0.0) 0 (0.0) 0 (0.0) 49 (35.5) 
Prior MI -- 24 (57.1) 2 (18.2) 31 (27.9) 27 (54.0) 11 (68.8) 17 (58.6) 0 (0.0) 38 (45.8) 93 (68.4) 
CHF -- 14 (32.6) 0 (0.0) 2 (1.8) 30 (58.8) 0 (0.0) -- 0 (0.0) 2 (2.4) 108 (88.5) 
Multi-vessel disease 0 (0.0) 42 (97.7) 0 (100.0) 111 (100.0) 51 (100.0) 16 (100.0) 30 (0.0) 0 (0.0) 83 (100.0) 116 (84.1) 
Left main disease 0 (0.0) 0 (0.0) 0 (0.0) 5 (4.5) 0 (0.0) 16 (100.0) 0 (0.0) 0 (0.0) 0 (.0.0) 12 (8.9) 
Proximal LAD 
disease 
18 (100.0) 27 (62.8) 11 (100.0) 59 (53.2) 14 (27.5) 8 (50.0) 30 (100.0) 25 (100.0) 78 (94.0) 69 (51.1) 
No. diseased 
vessels, mean (SD) 
1 (0.0) 2.6 (0.5) 1 (0.0) 2.6 (0.5) 2.4 (0.5) 3.3 (0.8) 1.2 (0.4) 1 (0.0) 2.6 (0.5) 2.3 (0.8) 
Ejection Fraction, %, 
mean (SD) 
61.3 (14.1) 54.5 (12.5) 58.1 (5.9) 52.8 (5.3) 64.1 (11.1) 54.1 (5.0) 62.6 (13.5) 69.3 (3.2) 67.5 (9.2) 45.4(14.7) 
Elevated cardiac 
biomarkers on 
admission 
-- -- 0 (0.0) 29 (26.1) 0 (0.0) 1 (6.3) 0 (0.0) -- 0 (0.0) -- 
MI on admission 0 (0.0) 1 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (6.3) 0 (0.0) 0 (0.0) 38 (45.8) 40 (29.0) 
Unstable angina on 
admission 
3 (16.7) 32 (74.4) 1 (9.1) 104 (93.7) 10 (20.0) 11 (68.8)  6 (20.0) 0 (0.0) 0 (0.0) -- 
Table 1-Baseline characteristics.  Data are presented as n (%) unless otherwise noted. eGFR estimates for BARI were calculated as described in the methods. CKD-
chronic kidney disease, CHF-congestive heart failure, LAD-left anterior descending artery, MI-myocardial infarction, No-number, SD-standard deviation. Data on diabetes 
was not available for subjects in AMIST. Data on smoking was not available in AMIST, and was missing for 1 subject in LE MANS, and 39 subjects in the VA study.  
Hyperlipidemia was missing all AMIST subjects, 6 in BARI, 1 in Leipzig, and all VA subjects. Data on baseline hypertension was unavailable in AMIST and was missing for 
1 subject from Leipzig. Prior revascularization was unavailable for AMIST.  Prior MI was unavailable for AMIST, and was missing in 1 subject from BARI, 1 subject from 
GABI, 1 in Leipzig, and 2 in the VA study.  CHF was not available for AMIST participants and was missing in 16 subjects from the VA study.  Data on left main disease was 
missing in 3 VA subjects.  Proximal LAD was missing in 3 subjects in the VA study. Data on number of diseased vessels was missing in 3 subjects from the VA study.  
Ejection fraction was missing in 10 subjects in AMIST, 23 in GABI, 1 in Le MANS and 33 in the VA study.  Cardiac biomarkers at baseline were not available for AMIST, 
BARI, VA, and MASS 1 studies.  Unstable angina at admission was missing in 1 subject from GABI, and all subjects in the VA study.  
 
  
Charytan et al, CABG versus PCI in CKD 
Table 4.  Mortality risk with CABG compared to PCI 
Group  Crude 
HR 
95% CI P Value Adjusted 
HR 
95% CI P Value 
Overall (n=3993)  0.93 0.77, 1.12 0.43 0.92 0.76, 1.11 0.38 
Preserved kidney 
   Function (n=3467) 
 0.92 0.74, 1.13 0.42 0.90 0.73, 1.11 0.33 
Stage 3-5 CKD (n=526)  1.01 0.68, 1.49 0.98 0.99 0.67, 1.46 0.96 
Stage 3a CKD (n=389)  0.87 0.52, 1.45 0.60 0.79 0.47, 1.33 0.39 
Stage 3b-5CKD (n=137)  1.15 0.62, 2.13 0.67 1.29 0.68, 2.46 0.43 
CKD with multi-vessel 
disease* (n=419) 
 1.16 0.77, 1.75 0.49 1.10 0.73, 1.67 0.65 
CKD with single-vessel 
disease* (n=107) 
 0.33 0.07, 1.61 0.17 0.32 0.06, 1.76 0.19 
CKD proximal LAD 
disease* (n=342) 
 0.88 0.54, 1.43 0.61 0.94 0.57, 1.54 0.80 
CKD without proximal 
LAD disease* (n=185) 
 1.31 0.67, 2.56 0.43 1.15 0.57, 2.27 0.71 
All models were stratified by trial.  Multivariable models adjusted for treatment, age, diabetes, 
prior myocardial infarction, proximal left anterior descending artery disease, ejection fraction 
<40%, prior revascularization, and multi-vessel. *To avoid model overspecification, these 
subgroup models did not include terms for multi-vessel disease or proximal LAD disease, 
respectively.  CKD-chronic kidney disease. LAD-left anterior descending artery.  
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Table 5. Risk of myocardial infarction with CABG compared to PCI 
Group  Crude 
HR 
95% CI P Value Adjusted 
HR 
95% CI P Value 
Overall (n=3981)  0.90 0.75, 1.07 0.23 0.88 0.73, 1.05 0.16 
Preserved kidney  
   Function (n=3459) 
 0.98 0.81, 1.19 0.87 0.97 0.80, 1.17 0.72 
Stage 3-5 CKD (n=522)  0.49 0.30, 0.81 0.01 0.49 0.29, 0.82 0.01 
Stage 3a CKD (n=388)  0.68 0.37, 1.27 0.24 0.71 0.36, 1.39 0.31 
Stage 3b-5CKD (n=134)  0.27 0.11, 0.66 0.004 0.23 0.09, 0.58 0.002 
CKD with multi-vessel 
disease*  (n=416) 
 0.45 0.26, 0.79 0.01 0.43 0.24, 0.76 0.004 
CKD with single vessel 
disease* (n=106) 
 0.71 0.20, 2.47 0.59 1.09 0.24, 4.86 0.91 
CKD proximal LAD disease* 
(n=338) 
 0.39 0.19, 0.80 0.01 0.39 0.18, 0.82 0.01 
CKD without proximal LAD 
disease* (n=183) 
 0.64 0.31, 1.33 0.23 0.74 0.34, 1.64 0.46 
All models were stratified by trial.  Multivariable models adjusted for treatment, age, diabetes, 
prior myocardial infarction, proximal left anterior descending artery disease, ejection fraction 
<40%, prior revascularization, and multi-vessel. * To avoid model overspecification, these 
subgroup models did not include terms for multi-vessel disease or proximal LAD disease, 
respectively.  CKD-chronic kidney disease. LAD-left anterior descending artery  
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Table 6. Risk of repeat revascularization for CABG compared to PCI 
Group  Crude 
HR 
95% CI P Value Adjusted 
HR 
95% CI P Value 
Overall  (n=3912)  0.14 0.12, 0.17 <0.001 0.14 0.11, 0.17 <0.001 
Preserved kidney  
   Function (n=3405) 
 0.13 0.11, 0.16 <0.001 0.13 0.11, 0.16 <0.001 
Stage 3-5 CKD (n=507)  0.21 0.11, 0.40 <0.001 0.21 0.11, 0.39 <0.001 
Stage 3a CKD (n=371)  0.18 0.08, 0.41 <0.001 0.17 0.08, 0.40 <0.001 
Stage 3b-5CKD (n=136)  0.30 0.11, 0.85 0.02 0.25 0.09, 0.71 0.01 
CKD with multi-vessel 
disease* (n=400) 
 0.21 0.10, 0.46 <0.001 0.21 0.10, 0.46 <0.001 
CKD with single vessel 
disease* (n=107) 
 0.20 0.07, 0.62 0.01 0.19 0.06, 0.61 0.01 
CKD proximal LAD disease* 
(n=329) 
 0.19 0.09, 0.40 <0.001 0.18 0.09, 0.38 <0.001 
CKD without proximal LAD 
disease* (n=176) 
 0.25 0.07, 0.87 0.03 0.25 0.07, 0.92 0.04 
All models were stratified by trial.  Multivariable models adjusted for treatment, age, diabetes, 
prior myocardial infarction, proximal left anterior descending artery disease, ejection fraction 
<40%, prior revascularization, and multi-vessel. * To avoid model overspecification, these 
models did not include terms for multi-vessel disease or proximal LAD disease, respectively.  
CKD-chronic kidney disease. LAD
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Figure 1. Flow diagram of study selection 
Figure 2. Actuarial freedom from death, MI, or revascularization after CABG and PCI by clinical 
subset 
Event-Free Survival after CABG and PCI calculated using the Kaplan-Meier method. (A-C) 
Overall survival.  (D-F) Freedom from myocardial infarction.  (G-I) Freedom from repeat 
revascularization. Unadjusted (Cox) P values stratified by trial are provided.  CABG-dashed 
lines.  PCI-solid lines.  
Supplementary Methods 
Search Criteria and Identification of Eligible Trials 
Search Terms were as follows: a) “angioplasty or transluminal or percutaneous coronary).mp. 
[mp=ti, ab, tx, kw, ct, ot, sh, hw, nm, ui]”; and b) “coronary artery bypass.mp. [mp=ti, ab, tx, kw, 
ct, ot, sh, hw, nm, ui]”. Differences in opinion regarding inclusion or the rationale for individual 
citations were resolved by consensus.   
 
Data Extraction 
Using standardized spreadsheet with standard variable names and descriptions of 
requested data, investigators from each trial were contacted and asked to prepare and share 
data. The independent data sets were separately assessed, and baseline and outcome data 
from each trial was analyzed.  Trial investigators were re-contacted and queried to resolve any 
apparent differences between provided data sets and trial publications.  Following data 
cleaning, a composite data set including a variable to identify the trial source for each subject 
was assembled and used for all further analyses.  
 
Statistics and Analysis 
 Multiple imputations were created using the chained equations method and pooled using 
Barnard-Rubin adjusted degrees of freedom.1 It is critical to include the outcome in the 
imputation model to reduce bias.2 We therefore included an indicator for whether the 
observation was censored as well as the Nelson-Aalen estimator of cumulative hazard.3 In 
primary analyses, we calculated the Nelson-Aalen estimator treating all observations as 
independent. Sensitivity analyses in which we calculated the Nelson-Aalen estimator within 
each study separately yielded similar results.    
As a sensitivity analysis, we imputed under a linear multilevel model that employed 
random intercepts to account for a trial-specific underlying hazard of the event corresponding to 
the study’s unique population. The imputation model additionally included fixed effects and 
random slopes by study for all predictor variables of interest (except for the Nelson-Aalen 
estimator, which was modeled with only a fixed effect by study). There is not yet robust 
statistical methodology for multilevel imputation in the presence of both systematic missingness 
(meaning that a variable is completely missing within at least one trial) and sporadic 
missingness (meaning that a variable is sometimes observed and sometimes missing within at 
least one trial). Thus, for this approach, we excluded the trial (AMIST) with systematic 
missingness on any variable.  
Multiple imputation and survival analyses were performed in R (Version 3.1.0, R 
Foundation for Statistical Computing, Vienna, Austria)4-8 using the mice.impute.pmm and 
mice.impute.2l.norm methods in the mice imputation package.  All tests were two-sided, and we 
defined statistical significance using an alpha threshold of 0.05. 
 
Statistical Code 
R code for the primary analysis is provided below: 
The primary analysis was coded as follows:  
 
################################ MAKE IMPUTED DATASETS 
################################# 
 
###### Function: Impute Dataset with Specified Method and NA estimator 
###### 
 
# data: raw dataset 
# na.est: "NA.est.strat" or "NA.est.naive" 
# method: "2l.norm.me" for Resche-Rigon's MICE-RE, "2l.norm" for MICE's 
native 2l.norm, or "pmm" for MICE default 
 
impute = function( data, na.est, .method ) { 
   
  # use PI's name to generate seed for project 
  #set.seed(char2seed("Wolfgang"))   
   
  # keep only relevant NA estimator (delete anything else containing 
"NA.est") 
  na.names = names(data)[ grep("NA.est", names(data)) ]  # all variable 
names containing "NA.est" 
  ones.to.delete = na.names[na.names != na.est]  # delete all but the one 
we're actually using 
  #one.to.delete = switch(na.est, "NA.est.strat"="NA.est.naive", 
"NA.est.naive"="NA.est.strat") 
  d = data[, !names(data) %in% ones.to.delete] 
   
  # first fit normal MICE to get predictor matrix 
  ini = mice(d, maxit = 0) 
  pred = ini$predictorMatrix 
   
  # modify predictor matrix 
  pred[ pred==1 ] = 2  # give random effects to all variables used for 
prediction 
   
  # treat trial as the cluster term 
  col = pred[ , "trial_name"]; col[col==2] = -2; pred[, "trial_name"] = 
col 
   
  # fixed effects for N-A estimator 
  col = pred[ , na.est ]; col[col==2] = 1; pred[ , na.est ] = col 
   
  # change method to either Resche-Rigon or MICE's 2l.norm 
  method = ini$method; method[method == "pmm"] = .method 
   
  # convert class column to integer (required) 
  d$trial_name = as.integer(d$trial_name) 
  d$trial_name = as.integer(d$trial_name) 
   
  # impute with MICE-RE 
  imp = mice(d, maxit = 0, pred = pred, method = method) 
   
  return(imp) 
} 
 
 
################################# FIT ANALYSIS MODELS 
################################# 
 
###### Function: nicely round p-value ###### 
 
round_p_val = function(p) { 
  rounded = ifelse(p<0.001, "<0.001", round(p,3)) 
  return(rounded) 
} 
 
 
###### Function: fit models with different covariate and clinical subsets 
###### 
# Note: outcome variable must be called "outcome"; time variable must be 
called "time" 
 
# data = either the imputed data from mice if using MI or the original 
dataset if using CC 
# method = "MI.naive", "MI.strat", "CC" 
# sporadic.only = T/F 
# outcome.time = 1 or 5 
# subsets = logical statements defining each clinical subset 
# covariates.full = vector of covariates to adjust for in fully-adjusted 
model 
# covariates.min = vector of covariates to adjust for in minimally-
adjusted model 
 
 
fit_models = function(data, method, sporadic.only, outcome.time, subsets, 
covariates.full, covariates.min) { 
   
  if(!outcome.time %in% c("one", "five")) browser() 
   
  # initialize dataframe for results 
  d = as.data.frame(matrix(nrow=9, ncol=24)) 
   
  names(d) = c("Unadj.all.HR", "Unadj.all.CI", "Unadj.all.p", 
"Unadj.all.n",  
               "Min.all.HR", "Min.all.CI", "Min.all.p", "Min.all.n",  
               "Full.all.HR", "Full.all.CI", "Full.all.p", "Full.all.n",  
 
               "Unadj.some.HR", "Unadj.some.CI", "Unadj.some.p", 
"Unadj.some.n",  
               "Min.some.HR", "Min.some.CI", "Min.some.p", "Min.some.n",  
               "Full.some.HR", "Full.some.CI", "Full.some.p", "Full.all.n" 
                ) 
  rownames(d) = subsets 
   
  for ( r in 1:nrow(d) ) {  # row number 
    for( s in 1:(ncol(d)/4) ) {  # "set" number (every 3 cols is a "set" 
all using the same analysis) 
 
      ##### SET UP ##### 
        # type of covariate adjustment  
        strings = strsplit( names(d)[s*4], "[.]" ) 
        adj = strings[[1]][1] 
       
        # study subset 
        study.subset = strings[[1]][2] 
       
        # define appropriate clinical subset 
        clinical.subset = rownames(d)[r]  # pull subset we're using from 
shell dataframe 
         
        # define appropriate study subset 
        # when using MI, trial is coded as integer to please mice 
        if (method=="CC") exclude.studies = switch(study.subset, 
"all"="a", "some"=c("AMIST", "BARI")) 
        if (method %in% c("MI.naive", "MI.strat") ) exclude.studies = 
switch(study.subset, "all"="a", "some"=c(1, 2))  # the "a" is a hacky 
placeholder to avoid excluding any trials 
       
       
       
        # create formula string 
        covariates = switch(adj, "Unadj"="", "Full"=covariates.full, 
"Min"=covariates.min) 
        cat(outcome.time)  ## TEST ONLY 
        outcome.name = switch(outcome.time, "five"="outcome", 
"one"="outcome.1yr")  # get appropriate outcome name based on whether 
we're doing 1- or 5-yr outcome 
   
        LHS = paste( "Surv(time,", outcome.name, ") ~ treatment + 
strata(trial_name) +", collapse="") 
        RHS = paste(covariates, collapse=" + ") 
        formula = paste(LHS, RHS, collapse="" ) 
       
        # special case if no covariates 
        if (covariates=="") formula = paste( "Surv(time,", outcome.name, 
") ~ treatment + strata(trial_name)", collapse="") 
 
       
      ##### COMPLETE-CASES ##### 
        if (method=="CC") { 
          rs1 = coxph( eval(parse(text=formula) ), data=data, 
                 subset = ( eval( parse(text=clinical.subset) ) & (! 
trial_name %in% exclude.studies) ) 
                ) 
  
          # only proceed if all coefficients are non-NA (i.e. no singular 
predictors) 
          if ( !any( is.na( rs1$coef ) ) ) { 
             
            # get stats for dataframe 
            coef = rs1$coefficients["treatmentb.CABG"] 
            HR = round( exp( coef ), 2 ) 
            p = round_p_val( 
summary(rs1)$coefficients["treatmentb.CABG",5] )  # 1/20/16: PREVIOUSLY 
WAS COLUMN 6 
            CI.low = round( summary(rs1)$conf.int["treatmentb.CABG",3], 2 
) 
            CI.high = round( summary(rs1)$conf.int["treatmentb.CABG",4], 2 
) 
            CI = paste( CI.low, CI.high, sep=", ") 
            n = rs1$n 
             
            # put stats in dataframe 
            d[r, (s*4-3):(s*4) ] = c(HR, CI, p, n) 
          } else { 
            d[r, (s*4-3):(s*4) ] = c("sing", "sing", "sing", "sing") 
          } 
        } 
       
      ##### MULTIPLY-IMPUTED ##### 
        if ( method %in% c("MI.naive", "MI.strat") ) { 
           
          # not currently dealing with this based on simulation study 
results 
          if(method == "MI.strat") stop() 
   
          # decide which NA estimator variable to use (based on outcome 
time desired) 
            if ( (method == "MI.naive") & (outcome.time=="five") ) 
est.name = "NA.est.5yr" 
            if ( (method == "MI.naive") & (outcome.time=="one") ) est.name 
= "NA.est.1yr" 
             
          # decide which method to use (based on sporadic only vs. all 
trials) 
            if ( (method == "MI.naive") & (sporadic.only==TRUE) ) { 
              meth.imp="2l.norm" 
              d2 = data[ data$sporadic.only, ]  # cut down dataset to just 
sporadic trials 
            } 
             
            if ( (method == "MI.naive") & (sporadic.only==FALSE) ) { 
              meth.imp="pmm" 
              d2 = data  # keep same dataset 
            } 
           
          # make imputed data 
          d3 =  impute(d2, est.name, .method=meth.imp) 
           
          #m.imp.spor = impute(m[ m$sporadic.only, ], "NA.est.naive", 
.method="2l.norm") 
          #m.imp.all = impute(m, "NA.est.naive", .method="pmm") 
           
           
          # fit model to imputed datasets and pool 
          rs1 = with( d3, coxph( eval(parse(text=formula) ),  
                                   subset = ( eval( 
parse(text=clinical.subset) ) & (! trial_name %in% exclude.studies) ) 
                                   ) )   
          rs2 = pool(rs1) 
 
          # only proceed if df for all coefficients are non-NA (i.e. no 
singular predictors) 
          if ( !any( is.na( rs2$df ) ) ) { 
  
            # get stats for dataframe 
            coef = summary(rs2)["treatment2",1] 
            HR = round( exp(coef) , 2) 
            p = round_p_val( summary(rs2)["treatment2",5] ) 
            CI.low = round( exp(summary(rs2)["treatment2",6] ), 2 ) 
            CI.high = round( exp(summary(rs2)["treatment2",7] ), 2 ) 
            CI = paste( CI.low, CI.high, sep=", ") 
            n = rs1$analyses[[1]]$n  # take sample size from the first 
imputed analysis 
                         
            # put stats in dataframe 
            d[r, (s*4-3):(s*4) ] = c(HR, CI, p, n) 
            #d[r, (s*3-2):(s*3) ] = c(HR, CI, p) 
             
          } else { 
            d[r, (s*4-3):(s*4) ] = c("sing", "sing", "sing", "sing") 
          } 
        } 
    } 
  }  
  return(d) 
} 
 
 
# covariates for fully-adjusted model 
covariates.full = c("age_in_years", "diabetes", "prior_mi", 
"proximal_lad_disease", 
                    "ef40", "prior_revascularization", 
"multivessel_disease" ) 
 
# covariates for minimally-adjusted model 
# remove the 3 covariates that are systematically missing for any trial 
covariates.min = c("age_in_years", "proximal_lad_disease", 
                   "ef40", "multivessel_disease" ) 
 
# clinical subsets within which to fit model  
subsets = c("TRUE", "ckd==0", "ckd==1", "ckd3a==1", "ckd3b==1", 
            "ckd==1 & multivessel_disease==1", "ckd==1 & 
multivessel_disease==0",  
            "ckd==1 & proximal_lad_disease==1", "ckd==1 & 
proximal_lad_disease==0") 
 
 
 
 
# generate a csv file for every combination of scenarios 
setwd("/Users/mmathur/Dropbox/QSU/Mathur/WOLFGANG/Results") 
 
datasets = c("m", "re", "myo", "cv") 
imp.methods = c("MI.naive", "CC") 
outcome.t = c("one", "five") 
sporadic = c(TRUE, FALSE) 
endpoints = c("mortality", "revasc", "myo.infarc", "cv.hosp") 
 
# world's most inefficient set of for-loops 
for (d in datasets) { 
  for (i in imp.methods) { 
    for (time in outcome.t) { 
      for (s in sporadic) {  
         
        data = get(d) 
         
        string1 = switch(d, "m"="mortality", "re"="revasc", 
"myo"="myo.infarc", "cv"="cv.hosp") 
        string2 = paste(time, "year", sep=".") 
        string3 = ifelse(s, "spor.only", "all.trials") 
         
        full.string = paste(Sys.Date(), string1, i, string2, string3, 
".csv", sep="_") 
       
        cat( "\n\n", full.string ) 
         
        t = fit_models(data=data, method=i, sporadic.only=s, 
outcome.time=time, 
                       subsets, covariates.full, covariates.min) 
        write.csv(t, full.string ) 
         
      } 
    } 
  } 
} 
 
 
 
 
################################# MANUAL CHECKS FOR CODE ACCURACY 
################################# 
 
 
m.imp.all = impute(m, "NA.est.5yr", .method="pmm") 
myo.imp.all = impute(myo, "NA.est.5yr", .method="pmm") 
re.imp.all = impute(re, "NA.est.5yr", .method="pmm") 
cv.imp.all = impute(cv, "NA.est.5yr", .method="pmm") 
 
 
# spot-check main results in abstract 
# main outcome: mortality among all CKD subsets, PMM over all studies, 
fully adjusted 
rs1 = with(m.imp.all, coxph(Surv(time, outcome) ~ treatment + 
strata(trial_name) + age_in_years + 
                              diabetes + prior_mi + proximal_lad_disease + 
ef40 + 
                              prior_revascularization + 
multivessel_disease, subset=(ckd==1) ) ) 
summary(pool(rs1)) 
# matches :) 
 
# main outcome: myo infartcion among CKD 3b-5, PMM over all studies, fully 
adjusted 
rs1 = with(myo.imp.all, coxph(Surv(time, outcome) ~ treatment + 
strata(trial_name) + 
                                age_in_years + diabetes + prior_mi + 
                                proximal_lad_disease + ef40 + 
prior_revascularization + 
                                multivessel_disease, subset=(ckd==1) ) ) 
summary(pool(rs1)) 
# matches :) 
 
# main outcome: myo infartcion among CKD 3b-5, PMM over all studies, fully 
adjusted 
rs1 = with(myo.imp.all, coxph(Surv(time, outcome) ~ treatment + 
strata(trial_name) + 
                                age_in_years + diabetes + prior_mi + 
                                proximal_lad_disease + ef40 + 
prior_revascularization + 
                                multivessel_disease, subset=(ckd==0) ) ) 
summary(pool(rs1)) 
 
 
 
 
 
 
################################# FOREST PLOTS FOR HRs 
################################# 
 
# include only people with CKD in these plots 
 
# the "blahblah" is so that no studies get excluded by default 
make_forest_plot_stats = function(data, method, covariates, 
exclude.studies="blahblah" ) { 
   
  studies = levels(data$trial_name)[! levels(data$trial_name) %in% 
exclude.studies] 
   
  # initialize dataframe for results 
  results = as.data.frame( matrix( nrow=length(studies), ncol=7 ) ) 
  names(results) = c("trial", "HR", "CI.low", "CI.high", "significant", 
"singularity", "singular.vars") 
   
  # model formula 
  string1 = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
  string2 = paste("Surv(time, outcome) ~ treatment") 
  formula = ifelse(is.na(covariates), string2, string1) 
   
  for ( i in studies ) {  # for each trial 
    print(i) 
     
    if (method=="CC") { 
       
      # only keep data from intended trial AND CKD patients 
      temp = data[data$trial_name == i & data$ckd==1, ] 
       
      rs = coxph( eval(parse(text=formula) ), data=temp, subset=(ckd==1) ) 
       
      # get stats for dataframe 
      coef = rs$coefficients["treatmentb.CABG"] 
      HR = exp( coef ) 
      p = summary(rs)$coefficients["treatmentb.CABG",5] 
      CI.low = summary(rs)$conf.int["treatmentb.CABG",3] 
      CI.high = summary(rs)$conf.int["treatmentb.CABG",4] 
       
      # is HR significant at alpha=0.05? 
      significant = (p<=0.05) 
       
      # were there any NA coefficients in regression? (can arise due to 
singularities)  
      singular = any( is.na( rs$coef ) ) 
       
      # singular variables 
      singular.vars = paste( as.vector( names(rs$coef)[is.na(rs$coef)] ), 
collapse=", " )   
    } 
     
    if (method=="MI") {     
      # make imputed data 
      est.name = "NA.est.5yr" 
      meth.imp="pmm" 
      data.imp =  impute(data, est.name, .method=meth.imp) 
       
      # fit Cox model to imputed datasets and pool 
      trial.num = which( levels( data$trial_name ) == i )  # this is 
necessary because trial is coded numerically in MICE object 
      rs1 = with( data.imp, coxph( eval(parse(text=formula) ), subset = ( 
(trial_name == trial.num) & (ckd == 1) ) ) )   
       
      # were there any NA coefficients in regression? (can arise due to 
singularities)  
      singular = any( is.na( rs1$analyses[[1]]$coef ) ) 
       
      # singular variables 
      singular.vars = paste( as.vector( names( rs1$analyses[[1]]$coef )[ 
is.na( rs1$analyses[[1]]$coef ) ] ), collapse=", " ) 
       
      # only proceed with pooling if no singularities 
      if ( !singular ) { 
         
        rs2 = pool(rs1) 
         
        # get stats for dataframe 
        coef = summary(rs2)["treatment2",1] 
        HR = exp(coef) 
        p = summary(rs2)["treatment2",5] 
        CI.low = exp(summary(rs2)["treatment2",6] ) 
        CI.high = exp(summary(rs2)["treatment2",7] ) 
         
        # is HR significant at alpha=0.05? 
        significant = (p<=0.05) 
         
      } else { 
        HR = CI.low = CI.high = significant = NA 
      } 
    } 
    # put stats in results dataframe 
    results[ which( studies==i ), ] = c(i, as.numeric(HR), 
as.numeric(CI.low), as.numeric(CI.high), as.numeric(significant), 
singular, singular.vars) 
  } 
   
  # reorder the trials by HR for sexier plot 
  results.ord = results[ order( (results$trial!="Pooled, adjusted"), 
as.numeric(results$HR), decreasing=TRUE ), ] 
  results.ord$order = nrow(results.ord):1 
  results.ord$trial = as.factor(results.ord$trial) 
  #results.ord = results.ord[ , names(results.ord) != "order" ]  # remove 
order column 
  results.ord$trial = as.character(results.ord$trial) 
   
  return(results.ord) 
} 
 
 
# see which studies need to be excluded due to homogeneity on the outcome 
table(m$trial_name, m$outcome, m$ckd); exclude.studies.1 = c("AMIST", 
"CISOWSKI", "KOPIA") 
table(myo$trial_name, myo$outcome, myo$ckd); exclude.studies.2 = 
c("AMIST", "CISOWSKI", "KOPIA", "Leipzig MIDCAB vs. Stent", "GABI") 
table(re$trial_name, re$outcome, re$ckd); exclude.studies.3 = c("AMIST", 
"ERACI II", "MASS I", "CISOWSKI") 
table(cv$trial_name, cv$outcome, cv$ckd); exclude.studies.4 = 
c("CISOWSKI") 
 
# make forest plot stats for each outcome 
rs1 = make_forest_plot_stats(m, "MI", covariates=NA, exclude.studies = 
exclude.studies.1) 
rs1 = rbind(rs1, c("Pooled, crude", 1.01, .68, 1.49, 0, FALSE, "", -2) ) # 
manually add pooled estimate for CKD==1 (from tables) 
rs1$order = as.numeric(rs1$order)  # I don't know why the above causes 
order to become char... 
 
rs2 = make_forest_plot_stats(myo, "MI", covariates=NA, exclude.studies = 
exclude.studies.2) 
rs2 = rbind(rs2, c("Pooled, crude", 0.49, .3, .81, 1, FALSE, "", -2) ) # 
manually add pooled estimate for CKD==1 (from tables) 
rs2$order = as.numeric(rs2$order)  # I don't know why the above causes 
order to become char... 
 
rs3 = make_forest_plot_stats(re, "MI", covariates=NA, exclude.studies = 
exclude.studies.3) 
rs3 = rbind(rs3, c("Pooled, crude", .21, .11, .4, 1, FALSE, "", -2) ) # 
manually add pooled estimate for CKD==1 (from tables) 
rs3$order = as.numeric(rs3$order)  # I don't know why the above causes 
order to become char... 
 
rs4 = make_forest_plot_stats(cv, "MI", covariates=NA, exclude.studies = 
exclude.studies.4) 
rs4 = rbind(rs4, c("Pooled, crude", .45, .28, .71, 1, FALSE, "", -2) ) # 
manually add pooled estimate for CKD==1 (from tables) 
rs4$order = as.numeric(rs4$order)  # I don't know why the above causes 
order to become char... 
 
 
 
# coefficient forest plot parameters 
colors = c("black", "red") 
ticks = c(.001, .1, 1:9, (1:5)*10.0) 
limits = c( min(ticks), max(ticks) ) 
ylab = "Crude Hazard Ratio, CABG vs. PCI (95% CI)" 
title="" 
 
 
###### Mortality ###### 
ggplot(rs1, aes( y=as.numeric(HR), x=reorder(trial, order), 
shape=as.factor(trial=="Pooled, crude") ) ) + 
  geom_point(size=4) + geom_errorbar(aes(ymin=as.numeric(CI.low), 
ymax=as.numeric(CI.high) ), width=.1) + 
  scale_shape_manual(values=c(1, 19), name="") + 
  scale_y_log10(breaks=ticks, labels = ticks, limits=limits) +  
  geom_hline(yintercept = 1, linetype=2) + 
  coord_flip() + labs(title = title, x = "Trial", y = ylab) + 
  theme_bw() + scale_color_manual(values=colors) + 
  theme(axis.title = element_text(size=16) ) + 
  theme(legend.position="none") 
 
###### Myocardial Infarction ###### 
ggplot(rs2, aes( y=as.numeric(HR), x=reorder(trial, order), 
shape=as.factor(trial=="Pooled, crude") ) ) + 
  geom_point(size=4) + geom_errorbar(aes(ymin=as.numeric(CI.low), 
ymax=as.numeric(CI.high) ), width=.1) + 
  scale_shape_manual(values=c(1, 19), name="") + 
  scale_y_log10(breaks=ticks, labels = ticks, limits=limits) +  
  geom_hline(yintercept = 1, linetype=2) + 
  coord_flip() + labs(title = title, x = "Trial", y = ylab) + 
  theme_bw() + scale_color_manual(values=colors) + 
  theme(axis.title = element_text(size=16) ) + 
  theme(legend.position="none") 
 
###### Revascularization ###### 
ggplot(rs3, aes( y=as.numeric(HR), x=reorder(trial, order), 
shape=as.factor(trial=="Pooled, crude") ) ) + 
  geom_point(size=4) + geom_errorbar(aes(ymin=as.numeric(CI.low), 
ymax=as.numeric(CI.high) ), width=.1) + 
  scale_shape_manual(values=c(1, 19), name="") + 
  scale_y_log10(breaks=ticks, labels = ticks, limits=limits) +  
  geom_hline(yintercept = 1, linetype=2) + 
  coord_flip() + labs(title = title, x = "Trial", y = ylab) + 
  theme_bw() + scale_color_manual(values=colors) + 
  theme(axis.title = element_text(size=16) ) + 
  theme(legend.position="none") 
 
###### CV Hospitalization ###### 
ggplot(rs4, aes( y=as.numeric(HR), x=reorder(trial, order), 
shape=as.factor(trial=="Pooled, crude") ) ) + 
  geom_point(size=4) + geom_errorbar(aes(ymin=as.numeric(CI.low), 
ymax=as.numeric(CI.high) ), width=.1) + 
  scale_shape_manual(values=c(1, 19), name="") + 
  scale_y_log10(breaks=ticks, labels = ticks, limits=limits) +  
  geom_hline(yintercept = 1, linetype=2) + 
  coord_flip() + labs(title = title, x = "Trial", y = ylab) + 
  theme_bw() + scale_color_manual(values=colors) + 
  theme(axis.title = element_text(size=16) ) + 
  theme(legend.position="none") 
 
 
 
 
################################# INTERACTIONS OF INTEREST 
################################# 
 
##### NOT EDITED YET 
 
# Model 1: interaction of Tx with CKD vs. not 
# Model 2: interaction of Tx with CKD 3B vs. not 
# Model 3: within CKD subset, interactions of Tx*MVD and Tx*Prox LAD 
 
###### Function: Report Model Results Nicely ###### 
 
# m: unpooled results from mice 
# round: decimals to round to 
nice_report = function(m, round=2) { 
  pl = pool(m) 
   
  # get stats 
  HR = exp( summary(pl)[,1] ) 
  p = summary(pl)[,5] 
  CI.low = exp(summary(pl)[,6] ) 
  CI.high = exp(summary(pl)[,7] ) 
   
  rs = data.frame(HR, CI.low, CI.high, p) 
   
  return( round(rs, round) ) 
} 
 
 
###### Mortality ###### 
 
# Model 1 
covariates = c(covariates.full, "ckd*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m1 = with( m.imp.all, coxph( eval( parse(text=formula) ) ) ); summary(m1) 
print(formula); nice_report(m1) 
 
# Model 2 
covariates = c(covariates.full, "ckd3b*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m2 = with( m.imp.all, coxph( eval( parse(text=formula) ) ) ); summary(m2) 
print(formula); nice_report(m2) 
 
# Model 3 
covariates = c(covariates.full, "multivessel_disease*treatment", 
"proximal_lad_disease*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m3 = with( m.imp.all, coxph( eval( parse(text=formula) ), subset = 
(ckd==1) ) ); summary(m3) 
print(formula); nice_report(m3) 
 
 
###### Myocardial Infarction ###### 
 
# Model 1 
covariates = c(covariates.full, "ckd*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m1 = with( myo.imp.all, coxph( eval( parse(text=formula) ) ) ); 
summary(m1) 
print(formula); nice_report(m1) 
 
# Model 2 
covariates = c(covariates.full, "ckd3b*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m2 = with( myo.imp.all, coxph( eval( parse(text=formula) ) ) ); 
summary(m2) 
print(formula); nice_report(m2) 
 
# Model 3 
covariates = c(covariates.full, "multivessel_disease*treatment", 
"proximal_lad_disease*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m3 = with( myo.imp.all, coxph( eval( parse(text=formula) ), subset = 
(ckd==1) ) ); summary(m3) 
print(formula); nice_report(m3) 
 
 
###### Revascularization ###### 
 
# Model 1 
covariates = c(covariates.full, "ckd*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m1 = with( re.imp.all, coxph( eval( parse(text=formula) ) ) ); summary(m1) 
print(formula); nice_report(m1) 
 
# Model 2 
covariates = c(covariates.full, "ckd3b*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m2 = with( re.imp.all, coxph( eval( parse(text=formula) ) ) ); summary(m2) 
print(formula); nice_report(m2) 
 
# Model 3 
covariates = c(covariates.full, "multivessel_disease*treatment", 
"proximal_lad_disease*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m3 = with( re.imp.all, coxph( eval( parse(text=formula) ), subset = 
(ckd==1) ) ); summary(m3) 
print(formula); nice_report(m3) 
 
 
###### CV Hospitalization ###### 
 
# Model 1 
covariates = c(covariates.full, "ckd*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m1 = with( cv.imp.all, coxph( eval( parse(text=formula) ) ) ); summary(m1) 
print(formula); nice_report(m1) 
 
# Model 2 
covariates = c(covariates.full, "ckd3b*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m2 = with( cv.imp.all, coxph( eval( parse(text=formula) ) ) ); summary(m2) 
print(formula); nice_report(m2) 
 
# Model 3 
covariates = c(covariates.full, "multivessel_disease*treatment", 
"proximal_lad_disease*treatment") 
formula = paste("Surv(time, outcome) ~ treatment +", paste(covariates, 
collapse=" + ") ) 
m3 = with( cv.imp.all, coxph( eval( parse(text=formula) ), subset = 
(ckd==1) ) ); summary(m3) 
print(formula); nice_report(m3) 
 
 
 
 
 
Pre-specified Analytic Plan 
 A formal protocol for the meta-analysis was not specified or published prior to the receipt 
of data, and the study was not registered. Initial conceptions of the project prior to data 
acquisition specified obtaining patient-level data from trial investigators and the use of 
proportional hazards models to analyze the primary endpoint. Mortality and revascularization 
were included as primary endpoints, and the analysis of effect modification by left anterior 
descending artery disease or multi-vessel disease were similarly noted in these plans.  
Separate analyses of stage 4 and stage 3 CKD were considered during planning, but stage 3a 
and 3b CKD were analyzed instead given the limited numbers of subjects with stage 4 CKD in 
the final data set.  Because data on strokes was not readily available, data on MI is presented 
instead of a planned analysis of major adverse cardiovascular events (combined death, MI or 
stroke).   
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Supplementary Data 
Supplementary Table 1. Sensitivity analyses-risks of death with CABG compared to PCI, varying covariate adjustment and study inclusion—
imputed analyses 
Group Crude 
HR 
95% CI P M1 
HR 
95% CI P M2 
HR 
95% CI P M3 
HR 
95% CI P M4 HR 95% CI P M5 
HR 
95% CI P 
Overall 0.93 0.77, 1.12 0.43 0.94 0.78, 1.13 0.48 0.92 0.76, 1.11 0.38 0.92 0.77, 1.11 0.40 0.92 0.76, 1.10 0.36 0.91 0.75, 1.09 0.31 
Preserved 
GFR 
 
0.92 0.74, 1.13 0.42 0.93 0.75, 1.15 0.49 0.90 0.73, 1.11 0.33 0.91 0.74, 1.13 0.39 0.89 0.72, 1.11 0.31 0.88 0.71, 1.1 0.26 
CKD 3-5 1.01 0.68, 1.49 0.98 1.01 0.68, 1.49 0.98 0.99 0.67, 1.46 0.96 1.01 0.68, 1.49 0.97 0.99 0.67, 1.46 0.95 0.96 0.64, 1.42 0.82 
CKD 3a 0.87 0.52, 1.45 0.60 0.82 0.49, 1.37 0.44 0.79 0.47, 1.33 0.39 0.87 0.52, 1.45 0.60 0.79 0.47, 1.34 0.39 0.73 0.43, 1.24 0.25 
CKD 3b-5 1.15 0.62, 2.13 0.67 1.29 0.68, 2.44 0.44 1.29 0.68, 2.46 0.43 1.15 0.62, 2.13 0.67 1.30 0.68, 2.46 0.43 1.26 0.66, 2.4 0.49 
CKD & 
MVD* 
1.16 0.77, 1.75 0.49 1.14 0.75, 1.72 0.55 1.10 0.73, 1.67 0.65 1.16 0.77, 1.75 0.49 1.10 0.73, 1.66 0.66 1.05 0.69, 1.6 0.81 
CKD & 
SVD* 
0.33 0.07, 1.61 0.17 0.34 0.06, 1.94 0.23 0.32 0.06, 1.76 0.19 0.33 0.07, 1.61 0.17 0.32 0.06, 1.76 0.19 0.33 0.06, 1.79 0.20 
CKD & 
pLAD* 
0.88 0.54, 1.43 0.61 0.92 0.57, 1.5 0.75 0.94 0.57, 1.54 0.80 0.88 0.54, 1.43 0.61 0.94 0.57, 1.54 0.80 0.95 0.58, 1.56 0.83 
CKD 
without 
pLAD* 
1.31 0.67, 2.56 0.43 1.28 0.65, 2.54 0.48 1.15 0.57, 2.27 0.71 1.30 0.67, 2.54 0.44 1.13 0.57, 2.26 0.72 0.94 0.46, 1.91 0.86 
 
M1-all studies, only covariates without systematicsystematic missingness.  M2-all studies, full set of covariates imputed. M3-only studies without 
systematic missingness, unadjusted, M4-only studies without systematic missingness, fully adjusted with covariate imputation, M5- complete case 
analysis, fully adjusted.  Multivariable models adjusted for treatment, age, diabetes, prior myocardial infarction, proximal left anterior descending 
artery disease, ejection fraction <40%, prior revascularization, and multi-vessel disease. To avoid singular regression coefficients, these subgroup 
models did not include terms for multi-vessel disease or proximal LAD disease, respectively.  GFR-glomerular filtration rate.  CKD-chronic kidney 
disease. 3-5-stage 3-5 CKD.  3b-5-stage 3b-5 CKD. MVD-multivessel disease.  SVD-single vessel disease. pLAD-proximal left anterior descending 
artery disease. 
 
Supplementary Table 2. Supplementary analyses-crude and adjusted risks of myocardial infarction with CABG compared to PCI—imputed 
analyses 
Group Crude 
HR 
95% CI P M1 
HR 
95% CI P M2 
HR 
95% CI P M3 
HR 
95% CI P M4 HR 95% CI P M5 
HR 
95% CI P 
Overall 0.90 0.75, 1.07 0.23 0.89 0.75, 1.07 0.22 0.88 0.73, 1.05 0.16 0.90 0.75, 1.08 0.27 0.88 0.74, 1.06 0.18 0.88 0.74, 1.06 0.19 
Preserved 
GFR 
 
0.98 0.81, 1.19 0.87 0.98 0.81, 1.19 0.84 0.97 0.80, 1.17 0.72 0.99 0.82, 1.2 0.93 0.97 0.8, 1.18 0.79 0.98 0.8, 1.19 0.83 
CKD 3-5 0.49 0.30, 0.81 0.01 0.49 0.29, 0.81 0.01 0.49 0.29, 0.82 0.01 0.49 0.3, 0.81 0.01 0.50 0.3, 0.84 0.01 0.46 0.27, 0.78 0.004 
CKD 3a 0.68 0.37, 1.27 0.24 0.75 0.38, 1.46 0.40 0.71 0.36, 1.39 0.31 0.69 0.37, 1.28 0.24 0.71 0.36, 1.41 0.33 0.63 0.31, 1.28 0.20 
CKD 3b-5 0.27 0.11, 0.66 0.004 0.24 0.1, 0.59 0.00 0.23 0.09, 0.58 0.002 0.27 0.11, 0.66 0.00 0.22 0.09, 0.57 0.00 0.21 0.08, 0.55 0.001 
CKD & 
MVD* 
0.45 0.26, 0.79 0.01 0.45 0.26, 0.81 0.01 0.43 0.24, 0.76 0.004 0.45 0.26, 0.79 0.01 0.44 0.24, 0.77 0.01 0.41 0.23, 0.74 0.003 
CKD & 
SVD* 
0.71 0.20, 2.47 0.59 0.64 0.18, 2.27 0.49 1.09 0.24, 4.86 0.91 0.71 0.2, 2.47 0.59 1.13 0.24, 5.23 0.88 1.60 0.32, 8.09 0.57 
CKD & 
pLAD* 
0.39 0.19, 0.80 0.01 0.39 0.19, 0.8 0.01 0.39 0.18, 0.82 0.01 0.38 0.18, 0.79 0.01 0.39 0.19, 0.83 0.01 0.38 0.18, 0.81 0.01 
CKD 
without 
pLAD* 
0.64 0.31, 1.33 0.23 0.62 0.29, 1.35 0.23 0.74 0.34, 1.64 0.46 0.64 0.31, 1.34 0.24 0.74 0.33, 1.65 0.47 0.66 0.3, 1.48 0.32 
 
 
M1-all studies, only covariates without systematic missingness.  M2-all studies, full set of covariates imputed. M3-only studies without systematic 
missingness, unadjusted, M4-only studies without systematic missingness, fully adjusted with covariate imputation, M5- complete case analysis, 
fully adjusted.  Multivariable models adjusted for treatment, age, diabetes, prior myocardial infarction, proximal left anterior descending artery 
disease, ejection fraction <40%, prior revascularization, and multi-vessel disease. To avoid singular regression coefficients, these subgroup models 
did not include terms for multi-vessel disease or proximal LAD disease, respectively.  GFR-glomerular filtration rate.  CKD-chronic kidney disease. 
3-5-stage 3-5 CKD.  3b-5-stage 3b-5 CKD. MVD-multivessel disease.  SVD-single vessel disease. pLAD-proximal left anterior descending artery 
disease.  
Supplementary Table 3. Supplementary analyses- crude and adjusted risks of repeat revascularization with CABG compared to PCI—imputed 
analyses 
Group Crude 
HR 
95% CI P M1 
HR 
95% CI P M2 
HR 
95% CI P M3 
HR 
95% CI P M4 HR 95% CI P M5 
HR 
95% CI P 
Overall 0.14 0.12, 0.17 <0.001 0.14 0.12, 0.17 <0.001 0.14 0.11, 0.17 <0.001 0.14 0.12, 0.17 <0.001 0.14 0.12, 0.17 <0.001 0.14 0.12, 0.17 <0.001 
Preserved 
GFR 
 
0.13 0.11, 0.16 <0.001 0.13 0.11, 0.16 <0.001 0.13 0.11, 0.16 <0.001 0.13 0.11, 0.16 <0.001 0.13 0.11, 0.16 <0.001 0.13 0.11, 0.16 <0.001 
CKD 3-5 0.21 0.11, 0.40 <0.001 0.21 0.11, 0.39 <0.001 0.21 0.11, 0.39 <0.001 0.21 0.11, 0.4 <0.001 0.21 0.11, 0.39 <0.001 0.21 0.11, 0.41 <0.001 
CKD 3a 0.18 0.08, 0.41 <0.001 0.18 0.08, 0.41 <0.001 0.17 0.08, 0.40 <0.001 0.18 0.08, 0.41 <0.001 0.18 0.08, 0.40 <0.001 0.19 0.08, 0.43 <0.001 
CKD 3b-5 0.30 0.11, 0.85 0.02 0.26 0.09, 0.75 0.01 0.25 0.09, 0.71 0.01 0.30 0.11, 0.85 0.02 0.25 0.09, 0.71 0.01 0.25 0.09, 0.71 0.01 
CKD & 
MVD* 
0.21 0.10, 0.46 <0.001 0.21 0.10, 0.46 <0.001 0.21 0.10, 0.46 <0.001 0.21 0.1, 0.46 <0.001 0.21 0.10, 0.46 <0.001 0.22 0.1, 0.47 <0.001 
CKD & 
SVD* 
0.20 0.07, 0.62 0.01 0.20 0.07, 0.62 0.01 0.19 0.06, 0.61 0.01 0.20 0.07, 0.62 0.01 0.19 0.06, 0.60 0.01 0.21 0.07, 0.63 0.01 
CKD & 
pLAD* 
0.19 0.09, 0.40 <0.001 0.19 0.09, 0.39 <0.001 0.18 0.09, 0.38 <0.001 0.19 0.09, 0.4 <0.001 0.18 0.09, 0.38 <0.001 0.18 0.09, 0.39 <0.001 
CKD 
without 
pLAD* 
0.25 0.07, 0.87 0.03 0.25 0.07, 0.9 0.03 0.25 0.07, 0.92 0.04 0.24 0.07, 0.86 0.03 0.25 0.07, 0.93 0.04 0.29 0.08, 1.09 0.07 
 
M1-all studies, only covariates without systematic missingness.  M2-all studies, full set of covariates imputed. M3-only studies without systematic 
missingness, unadjusted, M4-only studies without systematic missingness, fully adjusted with covariate imputation, M5- complete case analysis, 
fully adjusted.  Multivariable models adjusted for treatment, age, diabetes, prior myocardial infarction, proximal left anterior descending artery 
disease, ejection fraction <40%, prior revascularization, and multi-vessel disease. To avoid singular regression coefficients, these subgroup models 
did not include terms for multi-vessel disease or proximal LAD disease, respectively.  GFR-glomerular filtration rate.  CKD-chronic kidney disease. 
3-5-stage 3-5 CKD.  3b-5-stage 3b-5 CKD. MVD-multivessel disease.  SVD-single vessel disease. pLAD-proximal left anterior descending artery 
disease. 
 
 
Supplementary Table 4. Results of eligible Trials  
Trial Overall Mortality Myocardial Infarction Revascularization Follow-Up 
Time 
Number 
Subjects 
RR 95% CI RR 95% CI RR 95% CI   
Excluded Trials         
Syntax1 1.24 0.78, 1.98 1.46 0.92, 2.33 2.29 1.67, 3.14 1 Year 1800 
Stent or Surgery2 2.82 1.27, 6.27 NC NC 3.45 2.34, 5.08 ≤4 Years 988 
SIMA3 0.48 0.04, 5.11 1.43 0.25, 8.24 NC NC Approximately 
3 Years 
123 
RITA 14 0.85 0.56, 1.28 1.46 0.98, 2.17 4.00 0.89, 17.93 ≤8.7 Years 1011 
Octopus5 NC NC 1.24 0.39, 3.95 4.80 1.41, 16.34 1 Year 280 
Myoprotect I6 0.91 0.31, 2.71 NC NC 6.39 0.86, 47.70 1 Year 44 
Goy et al7 2.91 0.31, 27.29 2.59 0.72, 9.34 83.00 4.70-12.00 2 Years 134 
Grip et al8 NC NC 0.92 0.06, 14.09 1.34 0.24, 7.38 6 Months 53 
Kim et al9 1.00 0.15, 6.82 NC NC 7.00 0.89, 54.83 1 Year 100 
Hong et al10 NC NC 0.59 0.08, 4.07 1.76 0.19, 16.57 6 Months 189 
French 
Monocentric11 
1.25 0.52, 2.99 NC NC 6.33 1.96, 20.52 5 Years 159 
ERACI I12 2.03 0.53, 7.77 NC NC 5.84 2.14, 15.93 3 Years 127 
EAST13 1.14 0.54, 2.41 NC NC 3.82 2.63, 5.55 3 Years 392 
Drenth et al14 NC NC 5.00 0.61, 41.31 4.00 0.89, 17.93 1.9-3.9 Years 102 
CARDIA15 1.00 0.38, 2.62 1.79 0.95, 3.35 6.00 2.37, 15.21 1 Year 510 
CABRI16 1.42 0.73, 2.76 1.42 0.80, 2.54 5.23 3.90, 7.03 1 Year 1054 
ARTS17 0.89 0.45, 1.77 1.29 0.80, 2.06 5.52 3.59, 8.49 1 Year 1205 
Relative risk of death, myocardial infarction or repeat revascularization as derived from primary publications of 
trials comparing PCI and CABG.  NC-Not-calculable directly from information in the publication.  Relative risks 
were extracted directly from the cited manuscripts, calculated from reported event rates, or estimated from 
Kaplan-Meir estimates of survival according to data available.   
Supplementary Table 5. Design features of non-included trials 
Characteristic Syntax1 Stent or 
Surgery2 
SIMA3 RITA 14 Octopus5 Myoprotect 
I6 
Goy7 Grip8 Kim9 Hong10 
Central randomization + + NR + NR + NR NR NR NR 
Concealed 
randomization 
+ + NR - NR NR NR NR NR NR 
Blinded outcomes 
assessment 
NR + NR + + NR NR NR NR NR 
Intention to treat 
analysis 
+ + + + + NR + NR NR NR 
Stents used +* +* +* + + +* + + +* +* 
Off-pump bypass - + + - + - - +* +* +* 
LIMA + + + + + NR + + +* +* 
Enrollment Period 2005-2007 1996-1999 1994-1998 1998-1991 1998-2000 1998-2001 1989-1993 NR 2000-2001 2003 
Single vessel disease 
only 
- - + - - - + + + + 
Multi-vessel disease 
only 
+ + - - - - - - - - 
Single or multi-vessel 
disease 
- - - + + + - - - - 
Left main disease + + - - - +*† - - - - 
Characteristic French 
Monocentric
11 
ERACI I12 EAST13 Drenth14 CARDIA15 CABRI16 ARTS17    
Central randomization NR + NR NR + - +    
Concealed 
randomization 
NR NR NR NR + NR NR    
Blinded outcomes 
assessment 
NR NR + NR + NR NR    
Intention to treat 
analysis 
NR NR + + + + +    
Stents used NR - - +* + + +*    
Off-pump bypass NR - - +* + NR NR    
LIMA NR + NR +* + NR +    
Enrollment Period 1989-1993 1988-1990 1987-1990 1997-1999 2002-2007 NR 1997-1998    
Single vessel disease 
only 
- - - + - - -    
Multi-vessel disease 
only 
+ + + - - + +    
Single or multi-vessel 
disease 
- - - - + - -    
Left main disease - - - - - - -    
NR-not recorded.  LIMA-left internal mammary artery. *Required by protocol.  †Left main or left main equivalent require
Supplementary Figure Legends 
Supplementary Figure 1 Within-trial risk of all-cause mortality with CABG compared with PCI 
among individuals with CKD  
 
Crude HRs in are provided as within study homogeneity on individual covariates precludes 
within study calculation of fully-adjusted HRs using the same model across each study. Some 
studies are not shown due to near-homogeneity on the outcome, which would cause model 
overspecification. 
 
Supplementary Figure 2 Within-trial risk of myocardial infarction with CABG compared with 
PCI among individuals with CKD  
 
Crude HRs in are provided as within study homogeneity on individual covariates precludes 
within study calculation of fully-adjusted HRs using the same model across each study. Some 
studies are not shown due to near-homogeneity on the outcome, which would cause model 
overspecification. 
 
Supplementary Figure 3 Within-trial risk of repeat revascularization with CABG compared with 
PCI among individuals with CKD  
Crude HRs in are provided as within study homogeneity on individual covariates precludes 
within study calculation of fully-adjusted HRs using the same model across each study. Some 
studies are not shown due to near-homogeneity on the outcome, which would cause model 
overspecification. 
 
Supplementary Figure 4 Within-trial risk of cardiovascular hospitalization with CABG 
compared with PCI among individuals with CKD  
 
Crude HRs in are provided as within study homogeneity on individual covariates precludes 
within study calculation of fully-adjusted HRs using the same model across each study. Some 
studies are not shown due to near-homogeneity on the outcome, which would cause model 
overspecification. 
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